anti-Vibrio cholerae O1 Ogawa & Inaba antibody product blog
Tags: Antibody; Monoclonal Antibody; Vibrio cholerae O1 Ogawa & Inaba; anti-Vibrio cholerae O1 Ogawa & Inaba antibody;
The Vibrio cholerae O1 Ogawa & Inaba n/a (Catalog #MBS834169) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s Vibrio cholerae O1 Ogawa & Inaba can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Lateral Flow. Researchers should empirically determine the suitability of the Vibrio cholerae O1 Ogawa & Inaba n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Mouse monoclonal Vibrio cholerae O1 Ogawa & Inaba antibody.
Biological Significance: In many African countries, V. cholerae O1 serotype Ogawa has been the strain most frequently isolated and associated with cholera outbreaks. The toxigenic Inaba serotype of Vibrio cholerae O1 biotype El Tor reappeared in India in 1998 and 1999, almost 10 years after its last dominance in Calcutta in 1989. The Ogawa and Inaba serotypes of V. cholerae O1 differ only by a 2-O-methyl group that is present in the non-reducing terminal sugar of the Ogawa O-specific polysaccharide (O-SP) of the LPS, but is absent from the Inaba O-SP. Immunogen: Cholera O1 Ogawa & Inaba antibody was raised in Mouse using Vibrio cholerae O1 serotype Ogawa & Inaba as the immunogen. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing Vibrio cholerae O1 Ogawa & Inaba are readily searchable from our website. Different antibodies against the same target such as Vibrio cholerae O1 Ogawa & Inaba may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.